Meta: In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

A new combination treatment may offer a promising option for patients with relapsed or refractory cutaneous T-cell lymphoma ...

Autolus Therapeutics plc (NASDAQ: AUTL) is one of the best biotech penny stocks to buy right now. On July 21, analyst Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics plc ...

Regeneron Pharmaceuticals Inc. disclosed within a positive second-quarter earnings report that it had received a complete response letter (CRL) two days earlier from the U.S. FDA for its bispecific ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

J&J and Legend’s first DTC commercial for Carvykti underscores the emotional toll multiple myeloma patients face when they ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ ...